Form 4: Nurix Legal Chief Sells Shares for Tax Obligations

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 4,421 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on January 30, 2026.
• She acquired a total of 10,534 shares of common stock through the vesting of restricted stock units (RSUs) at an exercise price of $0.
• Concurrently, she disposed of 4,421 shares of common stock in two separate transactions.
• The sales were executed at weighted average prices of $16.5826 for 4,333 shares and $17.3717 for 88 shares.
• These sales were non-discretionary "sell to cover" transactions, mandated by Nurix's equity incentive plans to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Christine Ring beneficially owns 57,010 shares of Nurix Therapeutics common stock directly.
• She also holds remaining derivative securities in the form of Restricted Stock Units totaling 46,475 shares (2,000, 18,750, and 25,725 shares from different grants).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine for executive compensation and tax management, not signaling a change in company fundamentals or executive confidence.

Positives

• Christine Ring continues to hold a significant number of shares (57,010) directly, indicating ongoing alignment with shareholder interests.
• The vesting of restricted stock units represents a form of compensation and retention for a key executive.
• The sales were non-discretionary, solely for tax withholding, rather than a voluntary reduction in ownership.

Negatives

• A total of 4,421 shares were sold, reducing the direct beneficial ownership from what it would have been without the tax obligation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and standard practice for executives receiving equity compensation, particularly restricted stock units, to meet tax obligations upon vesting. These transactions are generally not indicative of an executive's sentiment towards the company's future prospects, unlike discretionary sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sales are non-discretionary and for tax purposes, not a signal of lack of confidence. The executive maintains significant ownership.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The transactions reported are routine 'sell to cover' actions for tax purposes following RSU vesting, which is a common practice for executives. They do not reflect a discretionary decision to reduce exposure to the company's stock and therefore do not provide a strong signal for a 'buy' or 'sell' recommendation. The executive retains substantial beneficial ownership, suggesting continued alignment with company performance. Investors should 'hold' and look for more substantive operational or financial news for investment decisions.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Transaction, Christine Ring, Chief Legal Officer, Restricted Stock Units, RSU Vesting, Sell to Cover, Equity Incentive Plan, Beneficial Ownership